{"entity":{"id":"nct06225843","kind":"trial","name":"Sotevtamab (AB-16B5) Combined With FOLFOX as Neoadjuvant Treatment Prior to Resection of Colorectal Cancer Liver Metastasis","aka":["EGIA-003"],"tldr":"A phase 2 trial of FOLFOX in colorectal cancer, run by Alethia Biotherapeutics, now recruiting.","summary":"Sotevtamab (AB-16B5) Combined With FOLFOX as Neoadjuvant Treatment Prior to Resection of Colorectal Cancer Liver Metastasis is a phase 2 interventional study registered as NCT06225843 by Alethia Biotherapeutics, with 17 participants planned, started 2024-02-15 and due to reach its primary completion in 2026-03. Interventions recorded: Sotevtamab, FOLFOX. Conditions listed: Metastatic Colorectal Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06225843","url":"https://clinicaltrials.gov/study/NCT06225843"}],"tags":["ctgov-ingest"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":["folfox","sotevtamab"],"companies":["alethia-biotherapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06225843","phase":"2","setting":"A Proof-of-Concept Phase II Trial to Evaluate the EMT Inhibitor Sotevtamab Combined With FOLFOX Administered as Neoadjuvant Treatment Prior to Resection of Colorectal Cancer Liver Metastasis","sponsor":"Alethia Biotherapeutics","participation":[{"nct":"NCT06225843","source":"https://clinicaltrials.gov/study/NCT06225843","fetchedAt":"2026-10-07T16:54:19.620Z","studySha256":"512452a87ac225d6ec4896761bc35d22c290d73b3f1dd41eab67d58931cfe605","overallStatus":"RECRUITING","lastUpdatePosted":"2025-02-19","leadSponsor":"Alethia Biotherapeutics","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":17,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["Canada"]}],"started":"2024-02-15","startedType":"actual","enrolled":17,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06225843/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"drug":[{"id":"folfox","kind":"drug","name":"FOLFOX (5-FU, leucovorin, oxaliplatin)","route":"/drugs/folfox/"},{"id":"sotevtamab","kind":"drug","name":"Sotevtamab","route":"/drugs/sotevtamab/"}],"company":[{"id":"alethia-biotherapeutics","kind":"company","name":"Alethia Biotherapeutics","route":"/companies/alethia-biotherapeutics/"}]}}